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No complement receptor 1 stumps on podocytes in human on podocytes [4, 5], which have been shown to shed mi-
glomerulopathies. crovesicles bearing CR1 in the urine [6]. CR1 is a potent
Background. Type one complement receptor (CR1) is the complement-regulating protein. It is characterized by theonly physiological inhibitor of complement on podocytes. CR1
presence of multiple binding sites for C3b/C4b and foris lost in different glomerulopathies, in particular in lupus ne-
iC3b. In addition, CR1 is the major physiological cofac-phritis, in which it has been suggested that CR1 is removed
by proteolysis from the cell membrane. tor for the inactivation of fixed C3b to iC3b and C3dg
Methods. To define whether proteolytic cleavage of CR1 on by complement factor I. Thus, in the presence of factor I,
podocytes is a general phenomenon, we analyzed the expres- CR1 interrupts complement activation before inflam-sion of CR1 in different glomerulopathies using a monoclonal
matory mediators are released. On leukocytes, CR1 isantibody against epitopes present on the extracellular portion
an efficient receptor for complement-opsonized bacteria.of the molecule and a polyclonal antibody directed at the intra-
cellular tail of CR1. The two antibodies were applied on se- On erythrocytes, CR1 functions as an adhesion molecule
quential serial histologic sections of renal biopsy. capable of binding circulating immune complexes [7] and
Results. In normal glomeruli, the two antibodies provided presenting them to macrophages [8]. The function ofsimilar results, that is, strong staining of podocytes, and both
CR1 on podocytes remains unclear. One of its majorwere shown to recognize specifically CR1. Decreased expres-
roles might be to protect podocytes from complementsion of the extracellular portion of CR1 was observed in lupus
nephritis (8/8), focal and segmental glomerulosclerosis (FSGS; attack, since these cells do not express other complement
7/7), IgA nephritis (6/6), membranous glomerulonephritis regulatory proteins such as decay accelerating factor
(3/3), and minimal change disease (3/3). In each case, the de- (DAF), monocyte chemoattractant protein (MCP), orcreased expression was accompanied by a simultaneous de-
CD59 [9, 10].crease of the expression of the intracellular tail of CR1 (Spear-
man’s correlation coefficient rs 5 0.951, P , 0.001). This Complement receptor 1 of erythrocytes is lost in sev-
observation was confirmed by analyzing focal glomerular le- eral systemic diseases, including lupus erythematosus
sions on sequential serial sections. and chronic infections, particularly AIDS. The reduced
Conclusion. These data indicate that there are no CR1
number of CR1 on erythrocytes has been shown to be anstumps on podocytes, even in lupus nephritis, and suggest that
acquired process [11], most likely caused by proteolyticthe CR1 loss on podocytes is not due to consumption but to
decreased synthesis. A loss of CR1 synthesis might render cleavage occurring intravascularly [12]. In vitro CR1 is
podocytes highly sensitive to complement attack. more sensitive to various enzymes such as trypsin and
papain than are DAF and CD59 [12]. In addition, an
enzymatic cleavage is responsible for the release in
Complement receptor 1 (CR1, CD35) is an integral plasma of soluble CR1 from the surface of leukocytes
membrane glycoprotein present on most circulating cells, [13, 14]. In contrast, in urine, the CR1 is not found as a
including erythrocytes, polymorphonuclear leukocytes free soluble molecule, but is attached to the microvesicles
(PMNs), monocytes, B lymphocytes, and some T lym- released by podocytes [6].
phocytes [1–3]. In the kidney, CR1 localizes exclusively Complement receptor 1 expression is reduced in many
glomerulopathies, particularly in severe lupus nephritis
[4, 15] and collapsing glomerulosclerosis, although CR1Key words: CR1 stump, systemic lupus erythematosus, focal segmental
glomerulosclerosis, IgA nephritis, membranous nephritis, glycoprotein. disappears in many other glomerulonephritis (GN) as
well. In most instances, the loss of CR1 expression corre-Received for publication December 6, 1999
lates with the severity of the disease, as assessed by theand in revised form July 13, 2000
Accepted for publication July 19, 2000 degree of inflammation or tissue destruction [15]. The
mechanisms responsible for the disappearance of CR1Ó 2001 by the International Society of Nephrology
160
Moll et al: CR1 expression in glomerulopathies 161
have not yet been elucidated. Teixeira et al have sug- Immunoblotting analysis
gested that in lupus nephritis, CR1 was removed by pro- Urinary vesicles treated or not with HLE 9 mg and 18
teolytic cleavage [16]. However, urinary CR1 is dimin- mg, tail peptide and recombinant soluble CR1 (kindly
ished and not increased under such circumstances [6]. provided by U. Ryan, AVANT Immunotherapeutics,
The present work was undertaken to analyze the Inc., Needham, MA, USA) were electrophoresed under
mechanism underlying the loss of CR1 on podocytes in nonreducing conditions on sodium dodecyl sulfate-poly-
different glomerulopathies. For this purpose, we simulta- acrylamide gel electrophoresis (SDS-PAGE). Proteins
neously studied the expression of the extracellular por- were blotted onto nitrocellulose membranes. After block-
tion of CR1 (extra-CR1) as well as the intracellular tail ing with 7% milk/phosphate-buffered saline (PBS), blots
(intra-CR1) in normal and diseased kidneys. were incubated in presence of the monoclonal anti-extra-
cellular CR1 antibody (3D9), the polyclonal anti-intra-
cellular CR1 tail antibody (anti-CR1 tail IgG), or theMETHODS
rabbit preimmune IgG, followed by incubation with bio-
Antibodies tinylated donkey anti-rabbit IgG and streptavidin-perox-
ydase. Blots were revealed with a chemiluminescentThe presence of the extracellular portion of CR1 was
system (ECL detection reagent; Amersham, Arlingtonassessed using a monoclonal anti-CR1 antibody (3D9),
Heights, IL, USA).which recognizes an epitope near the C3b/C4b binding
site [17].
Kidney biopsiesA polyclonal anti-CR1 tail antibody was produced in
Thirty-six renal biopsy specimens taken between 1989rabbits. The sequence corresponding to the 43 amino
and 1999 were selected from the files of the Departmentacids of the intracellular part of the human CR1 protein
of Pathology (Kantonsspital, Basel, Switzerland). Nor-(position K1997 to P2039 5 CR1 tail; Genbank Y00816)
mal renal tissue was obtained from normal parts of twowas amplified by polymerase chain reaction (PCR) and
nephrectomies performed for renal cell carcinoma. Sev-cloned into a pGEX-5X-1 vector. The tail was expressed
eral different glomerulopathies and nephropathies wereas a fusion protein with glutathione S-transferase in
studied: eight lupus nephritis (1 class II according to theEscherichia coli and was purified through a Gluthatione
World Health Organization classification, 4 class III, andSepharose 4B column. After cleavage of the glutathione
3 class IV), three Wegener’s disease, three IgA nephritis,S-transferase with factor Xa, the purified tail was used for
three Henoch-Scho¨nlein’s purpura, three membranousimmunization. Preimmune and postimmune IgGs were
glomerulonephritis (MGN), three minimal change dis-purified from the sera of the rabbits through a protein
ease (MCD), three Alport’s syndrome, seven FSGS, andG column. The characterization of the polyclonal anti-
three acute interstitial nephritis.tail antibody is described elsewhere.
Two monoclonal anti-human B-cell antibodies (CD20 Immunohistochemistry
and CD21; Dako, Copenhagen, Denmark) were used as
Frozen 3 mm histologic sections obtained with a cryo-positive internal controls for the staining of B cells in
stat were dried at room temperature and fixed in acetonetonsil sections.
for 10 minutes. For the detection of the CR1 extracellularA monoclonal anti-human podocalyxin antibody (kindly
part (extra-CR1) in renal podocytes, the sections were
provided by Dr. D. Kerjaschki, Department of Clinical incubated with the monoclonal 3D9 antibody at 1:2000
Pathology, University of Vienna, Vienna, Austria) was dilution for two hours at room temperature.
used as a positive internal control for the staining of the For the detection of the CR1 intracellular tail (intra-
podocytes in the different glomerulopathies. Expression CR1) in renal podocytes, the sections were incubated
of podocalyxin on glomerular epithelial cells is known with the polyclonal CR1 intracellular tail antibody at
to be preserved in various renal diseases, that is, lupus 1:100 dilution for two hours at room temperature.
nephritis, IgA nephritis, focal and segmental glomerulo- After incubation, the tissue sections were washed
sclerosis (FSGS), and minimal change disease [18]. twice in TBS-NaCl 1:10 and then incubated with a goat
A monoclonal anti-human C5b-9 antibody (Quidel, anti-polyvalent antibody conjugated with alkaline phos-
San Diego, CA, USA) was used for the staining of the phatase [UltraTek Alk-Phos (Anti-Polyvalent) Ready-
deposition of C5b-9 in the different glomerulopathies. To-Use, Medite, Nunningen, Switzerland] for 10 minutes
at room temperature, washed twice in buffer, incubated
Preparation of urinary vesicles with Fuchsin-AP substrate for 30 minutes, washed again
Urinary vesicles bearing CR1 were obtained from four times in buffer, and counterstained with Ha¨malun-
fresh voided urine as already described [6]. Some of them Mayer. The slides were mounted under a cover slip, and
were treated with human leukocyte elastase (HLE), the tissue was examined with a Leitz microscope (Zeiss,
Jena, Germany).which is known to induce fragmentation of CR1 [14].
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Serial sections were performed in most cases. used to immunize rabbits, and the anti-CR1 tail IgG
purified from the rabbits sera was tested by immunoblot-Positive controls included tonsil sections incubated
with monoclonal anti-human B-cell antibodies (CD20 and ting for its reactivity with the peptide and CR1 of urinary
vesicles (Fig. 1).CD21) at 1:40 and 1:400, respectively, dilution for two
hours at room temperature. Renal tissue sections were As expected, the monoclonal antibody 3D9 directed
against the extracellular portion of CR1 reacted with theincubated with a monoclonal anti-human podocalyxin
antibody at 1:4000 dilution for two hours at room temper- urinary CR1 (200 kD; Fig. 1A). The anti-CR1 tail IgG
reacted specifically with the tail peptide, giving a signalature. Podocalyxin, identified as a major sialoprotein in
the glycocalyx of human visceral glomerular epithelial at the expected size of the molecule (6 kD). It also
reacted with the urinary CR1 (200 kD), but not withcells [19], was used as a specific marker of the podocytes.
Negative controls included normal kidney and tonsil recombinant soluble CR1 (rsCR1), known to lack the
intracellular tail of the molecule (Fig. 1B).sections. Normal renal tissue was incubated with an irrel-
evant monoclonal antibody (anti-factor D) [20], the pre- The ability of the polyclonal anti-CR1 tail antibody
to recognize CR1 stumps was checked by immunoblot-immune rabbit IgG, the CR1 intracellular tail antibody
absorbed with the CR1 intracellular tail peptide, bovine ting and immunohistochemistry. Western blot using uri-
nary vesicles treated with HLE [14] specifically detectedserum albumin, and buffer alone. Tonsil sections were
incubated with the preimmune rabbit IgG and the CR1 two different CR1 fragments (one fragment of a size
comprised between 135 and 86 kD, one fragment of aintracellular tail antibody absorbed with the CR1 intra-
cellular tail peptide. size below 33 kD). Preimmune IgG of the same rabbits
showed no reactivity (Fig. 1C). ImmunohistochemistryFor the detection of the C5b-9 deposits in glomeruli,
the sections were incubated with the monoclonal anti- on tonsil sections provided a specific staining localized
mainly within the follicles corresponding to the staininghuman C5b-9 antibody at 1:100 dilution for 30 minutes
at room temperature. An indirect immunofluorescence detected with 3D9 as well as CD20 and CD21, two mono-
clonal antibodies reacting against B cells (data notmethod was applied, using a goat anti-mouse IgG-DTAF
at 1:40 dilution for 30 minutes as a second step. shown). In sections incubated with CR1 tail antibody
absorbed with the CR1 tail peptide or preimmune rabbit
Semiquantitative analysis of the staining intensity IgG, no staining was detected (data not shown).
All of the evaluations of the glomerular staining inten-
CR1 in normal kidneysities were done semiquantitatively by two different pa-
thologists blinded for the slides. All glomeruli of each The only glomerular cells expressing CR1 in the kid-
ney were podocytes (Fig. 2). 3D9, the monoclonal Abslide were evaluated according to a predefined grading
scale: Grade 3, defined as a normal staining according to reacting with the C3b binding sites of CR1 (that is, extra-
CR1) as well as the anti-CR1 tail IgG (that is, intra-the staining of the normal renal tissue (100%); Grade 2,
defined as a moderate decrease of the staining (,100%, CR1), provided indistinguishable staining results of the
podocytes. No podocyte staining was present with the.50%); Grade 1, defined as a severe decrease of the
staining (,50%, .10%); and Grade 0, defined as an use of different antibodies as negative controls (Fig. 2).
These data established that both portions of podocytesalmost complete absence of the staining (,10%). A
mean score of glomerular intensity was obtained for each CR1 could be revealed in normal tissue: the extracellular
portion (extra-CR1) with 3D9 mAb and the intracellularsection rounded to half grade (0, 0.5, 1, 1.5, 2, 2.5, 3).
Correlations were calculated with the Spearman’s corre- tail (intra-CR1) with the polyclonal rabbit anti-CR1 tail.
A specific tubular staining was observed with the poly-lation coefficient (rs) to determine the validity of the
semiquantitative assessment. P values less than 0.05 were clonal anti-CR1 tail antibody and was localized within
or on the luminal side of distal tubular cells (data notconsidered significant.
shown). In sections incubated with CR1 tail antibody
absorbed with the CR1 tail peptide, preimmune rabbit
RESULTS
IgG, monoclonal 3D9 antibody, or glutathione S-trans-
Characterization of the polyclonal anti-CR1 tail ferase alone, no tubular staining was detected.
antibody (intra-CR1)
CR1 in glomerulopathiesThe proteolytic cleavage of CR1 on podocytes would
be demonstrated by the combination of (1) the loss of The glomerular staining for both portions of CR1 was
markedly reduced in many patients with glomerulopa-the extracellular portion of CR1 and (2) the presence of
the remaining CR1 stump in the podocyte membrane. thies according to a semiquantitative evaluation per-
formed for each section by two different pathologistsTo demonstrate CR1 stumps, it was necessary to produce
an antibody reacting with the intracellular tail of CR1. blinded for the slides (Table 1). The Spearman’s correla-
tion coefficient (rs) between the two different patholo-The 43 amino acid peptide corresponding to this tail was
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Fig. 1. Immunoblotting analysis. (A) Immu-
noblotting analysis of urinary vesicles (UV;
5% acrylamide gel) with the monoclonal anti-
body 3D9 (dilution 1/2000). (B) Immunoblot-
ting analysis of the tail peptide (1 mg), recom-
binant soluble CR1 (rsCR1; 50 ng, 4 to 20%
acrylamide gradient gel) and UVs (12% acryl-
amide gel) with the polyclonal anti-CR1 tail
antibody (dilution 1/2000). (C) Immunoblot-
ting analysis of UVs treated or not with human
leukocyte elastase (HLE) 9 and 18 mg (4 to
20% acrylamide gradient gel) with the poly-
clonal anti-CR1 tail antibody (dilution 1/2000)
and with the rabbit preimmune IgG.
Fig. 2. Normal glomerulus. (A) 3D9, the monoclonal antibody (Ab) reacting with the C3b binding sites of CR1 (that is, the extracellular portion
of CR1), provided a strong specific staining of the podocytes. (B) The anti-CR1 tail IgG (that is, the intracellular portion of CR1) provided an
identical staining of the podocytes, although there was a weak background staining of most of the renal tissue. (C) Staining was abolished when
the tissue sections were incubated with an irrelevant mAb (anti-factor D) or when 3D9 was preincubated with rsCR1 (data not shown). (D) The
anti-CR1 tail IgG staining was abolished by preincubating the Ab with purified tail-peptide. (E) The preimmune IgG was negative as well (A–E,
magnification 3100).
gists was 0.938 (P , 0.001) for the extra-CR1 mean score glomerulopathies. The concomitant loss of staining for
the two Ab was best shown on sequential serial sectionsof glomerular intensity and 0.961 (P , 0.001) for the
intra-CR1 mean score of glomerular intensity. The de- (Fig. 3).
A complete loss of the staining was observed in areascreased staining for both portions of CR1 was observed
in all patients with lupus nephritis (1 class II according of synechia formation in FSGS (Fig. 4) or in crescents
in Wegener’s disease (data not shown). The loss of stain-to the World Health Organization classification, 4 class
III and 3 class IV), Wegener’s granulomatosis (3 cases), ing for the two Ab was observed even in the absence of
light microscopic alterations, such as in minimal changeIgA-GN (3 cases), Henoch-Scho¨nlein’s purpura (3 cases),
MGN (3 cases), MCD (3 cases), Alport’s syndrome (3 disease (Fig. 5 A, B) and in unaffected glomeruli in the
case of FSGS.cases), and FSGS (7 cases). The Spearman’s correlation
coefficient (rs) for the two pathologists between the ex- This marked reduction of the glomerular staining for
both portions of CR1 was in strong contrast to the un-tra- and the intra-CR1 mean score of glomerular inten-
sity was 0.951 (P , 0.001), indicating the concomitant changed glomerular staining for the podocalyxin, in
MCD (Fig. 5 C, D) as well as in MGN. As expected,decrease of staining for both portions of CR1 in all the
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Table 1. Semiquantitative evaluation of the complement receptor DISCUSSION
1 (CR1) staining in glomerulopathies
In this study, we have demonstrated that the decreased
CR1 CR1 tail glomerular expression of the extracellular portion ofKidney diseases Glomeruli (1)/(2)a (1)/(2)a
CR1 (extra-CR1) observed in different types of glomer-
LED class II 8 0/0.5 0/0
ulopathies was paralleled by a concomitant decrease ofclass III 4 1/1 1/0
class III 6 2/2 2/2 the intracellular tail of the molecule (intra-CR1). These
class III 8 1/1 1/1 results suggest that the decrease of podocyte CR1 is due
class III 4 1.5/1.5 1/1.5
to a reduced expression of the entire molecule and notclass IV 4 1.5/1.5 1/1.5
class IV 6 0.5/0.5 1/1 to a proteolytic cleavage of the extracellular part as ob-
class IV 9 2/1.5 1.5/1.5 served on leukocytes and erythrocytes.
Wegener’s disease 6 1.5/1.5 1.5/1.5
Glomerulopathies with and without prominent in-8 0/0 0.5/0.5
11 1.5/1.5 1.5/1.5 flammatory cell infiltration and/or intrinsic cell prolifera-
IgA nephritis 13 1.5/1.5 1.5/1.5 tion were analyzed, because the mechanism of CR1 loss
8 2/2 1.5/1.5
could differ from one type of disease to another. En-5 0.5/0.5 0.5/0.5
Henoch-Scho¨nlein’s purpura 13 1.5/0.5 1.5/1 zymes known to be released by these inflammatory or
12 0.5/1 0.5/0.5 intrinsic proliferative cells may be responsible for pro-11 2.5/3 2.5/2.5
teolytic cleavage of CR1, whereas direct damage to po-Membranous GN 18 0.5/0.5 0.5/0.5
7 1.5/1.5 1.5/1.5 docytes may reduce CR1 synthesis.
12 2/2.5 2/2 The degree of CR1 loss varied widely from one biopsyMinimal change disease 9 0.5/0.5 0.5/0.5
to another, according to the severity of the injury. How-10 1.5/2 1.5/1.5
9 1/1.5 0.5/0.5 ever, particularly striking was the observation that in all
Alport’s syndrome 2 2/2 2/2 cases, the loss of CR1 involved both portions of the4 0.5/0.5 0.5/0.5
molecule (extra-CR1 and intra-CR1), with no evidence5 2.5/2.5 2.5/2.5
FSGS 6 1/1 0.5/0.5 for CR1 stumps. This marked reduction of the glomerular
8 1/1.5 1/1
staining for both portions of CR1 was in strong contrast4 1.5/1.5 0.5/0.5
7 2/2 2/2 to the unchanged glomerular staining for the podoca-
1 2/2 2/2 lyxin. Although immunohistochemistry is a semiquanti-
6 0.5/0.5 0/0
tative method, reproducible and similar results were ob-8 2/2 2.5/2.5
Acute interstitial nephritis 6 3/3 2.5/2.5 tained in the different cases of the same glomerulopathy
8 3/3 3/3 and in different types of glomerulopathies. Thus, these
9 3/3 2.5/2.5
results suggest that mechanisms other than proteolysisNormal renal tissue 20 3/3 3/3
20 3/3 3/3 are responsible for the CR1 reduction in glomerulopa-
a Two different pathologists [(1) and (2)] blinded for the slides evaluated each thies. This hypothesis is further strengthened by the find-
glomerulus of all the sections according to a pre-defined grading scale: Grade 3 5 ing that the CR1-coated microvesicles physiologicallynormal staining (100%); Grade 2 5 moderate decrease of the staining (,100%,
.50%); Grade 1 5 severe decrease of the staining (,50%, .10%); Grade 0 5 released by the podocytes into urine are also reduced in
loss of the staining (,10%). The normal staining was defined according to the the glomerulopathies studied, for example, FSGS andstaining of the normal renal tissues. A mean score of glomerular intensity was
obtained for each section rounded to half grade (0; 0.5; 1; 1.5; 2; 2.5; 3). severe lupus nephritis [6]. In addition, the urinary CR1
Spearman’s correlation coefficients between the two different pathologists: in these patients was found to be fixed on the podocyters 5 0.938 (P , 0.001) for the extra-CR1 mean score of glomerular intensity, rs 5
0.961 (P , 0.001) for the intra-CR1 mean score of glomerular intensity. Spear- microvesicles and not soluble as would be the proteolyti-
man’s correlation coefficient for the two pathologists between the extra- and the
cally cleaved molecule [6]. However, the hypothesis ofintra-CR1 mean score of glomerular intensity: rs 5 0.951 (P , 0.001).
a CR1 enzymatic cleavage with a simultaneous and im-
mediate loss of the remaining stump cannot be excluded.
Finally, complete loss of CR1 was noted in areas of
podocalyxin staining was lost in areas of synechia forma- synechiae, for example, in FSGS and crescents, for exam-
tion in FSGS or in crescents in Wegener’s disease, corre- ple, in Wegener’s GN. These results confirm previous
sponding to the loss of CRA staining. Moreover, the loss studies [21] and are well explained by the absence of
of staining for both portions of CR1 was concomitant to podocytes in these types of lesions, as shown by the loss
the detection of C5b-9 glomerular deposits along the of podocalyxin staining.
glomerular basement membrane in both FSGS and MCD Our data are, however, in conflict with those reported
(3/6 FSGS, 3/3 MCD; data not shown). by Teixeira et al who showed CR1 stumps on podocytes
Finally, in patients with nephropathies without glo- simultaneously to the loss of the extracellular portion of
merular involvement, that is, acute interstitial nephritis, CR1 in lupus nephritis [16]. These contradictory results
the glomerular staining for the two Ab was not signifi- are difficult to explain, but may be due to the different
antibodies. The polyclonal antibody used by Teixeiracantly different from the normal kidneys (Table 1).
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Fig. 3. Different types of glomerulopathies. (A) Lupus nephritis (WHO IV; magnification 362). (B) IgA nephritis (magnification 3100). (C)
Membranous GN (magnification 3100). Concomitant and markedly reduced staining for 3D9, the monoclonal Ab reacting with the C3b binding
sites of CR1 (that is, extra-CR1, A1, B1, C1), as well as for the anti-CR1 tail IgG (that is, intra-CR1; A2, B2, C2).
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Fig. 4. Focal and segmental glomerulosclerosis (FSGS). In areas of synechia formation (arrow) in FSGS (A), a complete loss of the staining for
3D9, the monoclonal Ab reacting with the C3b binding sites of CR1 (that is, extra-CR1) (B) as well as the anti-CR1 tail IgG (that is, intra-CR1),
was observed (magnification 3100).
Fig. 5. Minimal change disease. The reduction of glomerular staining for the two antibodies (Ab), (A) 3D9, the monoclonal Ab reacting with the
C3b binding sites of CR1 (that is, extra-CR1), as well as (B) the anti-CR1 tail IgG (that is, intra-CR1), was observed even in the absence of light
microscopic alterations (magnification 3100). In contrast, the glomerular staining for the monoclonal Ab reacting with podocalyxin was strong
(C) in the same patient with minimal change disease and was unchanged in comparison with (D) normal renal tissue (magnification 3100).
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2. Fearon DT, Ahearn JM: Complement receptor type 1 (C3b/C4brecognized a neoepitope expressed by the truncated mol-
receptor; CD 35) and complement receptor type 2 (C3d/ Epstein-ecule and was of low affinity, which does not exclude an Barr virus receptor; CD21), in Current Topics in Microbiology and
unspecific binding [22]. Immunology (the Third Component of Complement) (vol 153),
edited by Lambris JD, Heidelberg, Springer Verlag, 1989, pp 83–98It is interesting that a concomitant decrease of both
3. Kazatchkine MD, Fearon DT: Deficiencies of human comple-the extra-CR1 and the intra-CR1 was observed even in
ment receptors type 1 (CR1, CD35) and type 2 (CR2, CD21).the absence of any light microscopy lesion of capillary Immunodef Rev 2:17–41, 1990
loops and podocytes in MCD and FSGS. In these glomer- 4. Kazatchkine MD, Fearon DT, Appay MD, et al: Immunohisto-
chemical study on the human glomerular C3b receptor in normalulopathies, podocytes are injured, and morphological al-
kidney and in seventy-five cases of renal diseases. J Clin Investterations, such as foot process fusion, vacuoles, and mi-
69:900–912, 1982
crovilli formation, can be observed by electron micro- 5. Fischer E, Appay MD, Cook J, et al: Characterization of human
scopy. These ultrastructural lesions might reflect a modi- C3 receptor as C3b/C4b complement type one (CR1) receptor.
J Immunol 136:1373–1377, 1986fication of the metabolism and/or cellular activity of the
6. Pascual M, Steiger G, Sadallah S, et al: Identification of mem-podocytes. Thus, we can speculate that the reduction
brane-bound CR1 (CD:35) in human urine: Evidence for its release
of CR1 might be due to a reduction of CR1 synthesis by glomerular podocytes. J Exp Med 179:889–899, 1994
secondary to a modification of the metabolism of the 7. Cosio FG, Shen XP, Birmingham DJ, et al: Evaluation of the
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J Immunol 145:4198–4206, 1990
of podocyte injury. 8. Walport MJ, Ng YC, Lachmann PJ: Erythrocytes transfused into
Although FSGS and MCD are thought to be T-cell– patients with SLE and haemolytic anaemia lose complement recep-
tor type 1 from their cell surface. Clin Exp Immunol 69:501–507,mediated diseases and not complement-mediated dis-
1987eases, glomerular deposition of C5b-9 [23, 24] and uri-
9. Ichida S, Yuzawa Y, Okada H, et al: Localization of the comple-
nary C5b-9 [25] are detected in both of these glom- ment regulatory proteins in the normal human kidney. Kidney Int
erulopathies. The significance of this deposition is un- 46:89–96, 1994
10. Nangaku M: Complement regulatory proteins in glomerular dis-clear. We can speculate that these deposits are favored
eases. Kidney Int 54:1419–1428, 1998by the down-regulation of CR1, which is known as the
11. Lach-Trifilieff E, Marfurt J, Schwarz S, et al: Complement
only physiological inhibitor of complement present on receptor 1 (CD35) on human reticulocytes: Normal expression in
systemic lupus erythematosus and HIV-infected patients. J Immu-podocytes. This down-regulation of CR1 might therefore
nol 162:7549–7554, 1999render podocytes more sensitive to complement attack
12. Pascual M, Danielsson C, Steiger G, et al: Proteolytic cleavageand contribute to cellular damage. of CR1 on human erythrocytes in vivo: Evidence for enhanced
In summary, we did not find any evidence for the cleavage in AIDS. Eur J Immunol 24:702–708, 1994
13. Danielsson C, Pascual M, French L, et al: Soluble complementformation of CR1 stumps on podocytes. In contrast, the
receptor type 1 (CR1) is released from leukocytes by surface cleav-data suggest quite strongly that the synthesis of CR1 is
age. Eur J Immunol 24:2725–2731, 1994reduced in injured podocytes. Whether the down-regula- 14. Sadallah S, Hess C, Miot S, et al: Elastase and metalloproteinase
tion of CR1 is only a marker of injured podocytes or activities regulate soluble complement receptor 1 release. Eur J
Immunol 29:3754–3761, 1999contributes to further damage remains speculative. How-
15. Emancipator SN, Iida K, Nussenzweig V, et al: Monoclonal anti-ever, since CR1 is the only complement regulatory pro-
bodies to human complement receptor (CR1) detect defects intein on the urinary side of the glomerulus, it is possible glomerular diseases. Clin Immunol Immunopathol 27:170–175,
that the loss of complement inhibition allows comple- 1983
16. Teixeira JE, Costa RS, Lachmann PJ, et al: CR1 stump peptidement proteins to damage podocytes further, particularly
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